Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Phase III Clinical Trial to Evaluate ILC (Inhaled Lipid-Cisplatin) for Patients with Small Cell Lung Cancer

Next Previous
X
Search
Trial Profile

A Pivotal Phase III Clinical Trial to Evaluate ILC (Inhaled Lipid-Cisplatin) for Patients with Small Cell Lung Cancer

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary)
  • Indications Small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Eleison Pharmaceuticals

    • Most Recent Events

    • 28 May 2021 According to an Eleison Pharmaceuticals media release, the companys ILC (Inhaled Lipid-Cisplatin) program is expected to begin this potentially pivotal phase III clinical trial in 2021 or 2022.
    • 21 Dec 2020 New trial record
    • 11 Dec 2020 According to an Eleison Pharmaceuticals media release, the companys ILC (Inhaled Lipid-Cisplatin) program is expected to begin a potentially pivotal phase II clinical trial in 2021 for patients with small cell lung cancer. Eleison is pleased to announce it recently received approval from the National Medical Products Administration (formerly known as the China FDA) to commence enrollment in China for this lung cancer study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top